Heart Failure

Cardiovascular Clinical Consult

Adult Immunization

Hepatic Disease 

Behcet’s Disease

Rare Disorders

Pediatric Immunization

Implementing The Topcon Ocular Telehealth Platform

Weight Management

Screening

Monkeypox

Guidelines

Men's Health

Panic Disorder  

Anxiety

Eating Disorders

Depression

Substance-related Disorders

ADHD

Psychiatry 

Seasonal Allergies

Allergy

Nutrition 

Pregnancy and Birth

Women's Health

Atrial Fibrillation

Cholesterol Disorders

Cardiovascular Disease

Hypertension

Cardiology

Substance Use

Child/Adolescent

Pediatrics

Kidney Disease

Genetics

Medical Cannabis

Complimentary & Alternative Medicine

Skin Diseases

Dermatology

Thyroid Disorders 

Diabetes

Diabetes Type 2

Insulin

Endocrinology 

Oral Medicine 

Otorhinolaryngologic Diseases

Fibromyalgia

Pain

Irritable Bowel Syndrome 

Inflammatory Bowel Disease

Gastrointestinal Disorders

Geriatrics

Coronavirus

Hepatitis C

Cold, Cough, and Flu

Bacterial Conjunctivitis

Immunization

Influenza

HIV AIDS

Sexually Transmitted Diseases

Infection

Osteoporosis

Imaging 

Musculoskeletal Disorders  

Obesity

Rheumatoid Arthritis

Arthritis

Gout

Rheumatology

Technology

Colorectal Cancer

Kidney Cancer

Lung Cancer

Melanoma

Skin cancer

Prostate Cancer

Breast Cancer

Cervical Cancer

Cancer

Nephrology

Anemia

Dementia

Epilepsy

Cerebrovascular Diseases

Headache and Migraine

Parkinson Disease

Alzheimer disease

Stroke

Mental Health

Headache

Migraine

Nervous System Diseases

Sleep Disorders

Neurology

Asthma

Cystic Fibrosis

COPD

Pneumonia

Respiratory Diseases

Pulmonology

News

All News

Office Procedures

Practice Management

Media

Around the Practice

Between the Lines

ConsultantLive

Expert Interviews

Institutional Insights

Medical World News

Podcasts

Primary View

Provider Toolkits

Readout360

Conferences

Conference Coverage

Conference Listing

Resources

Image IQ

Interactive Posters

Polls

Publications

Quizzes

Subscribe

CE/CME

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Gastroenterology

Infectious Disease

Men’s Health

Pain Management

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Telehealth

Value-based Care

Spotlight

Unmet Needs in Managing MDD

Interpreting Thyroid Function Tests

Using Thyroid Lab Tests

Testing & Screening to Optimize Men's Health

1rem

Authors

ABSTRACT: In general, the management of invasive pulmonaryaspergillosis is based on antifungal therapy and reversal of immunosuppression.Voriconazole is the preferred treatment inmost cases. Liposomal preparations of amphotericin B, caspofungin,and posaconazole are alternatives in patients whocannot tolerate voriconazole or have refractory aspergillosis.Prophylaxis in high-risk patients has gained popularity withthe availability of oral extended-spectrum azoles; posaconazoleis approved for prophylaxis in patients with acute leukemia,myelodysplastic syndrome, and graft versus host disease.(J Respir Dis. 2008;29(11):429-434)

Invasive pulmonary aspergillosis, part 2: Treatment

ABSTRACT: The diagnosis of invasive pulmonary aspergillosis remainschallenging because of atypical clinical presentations,comorbid diseases, and the difficulty in culturing Aspergillus bystandard microbiological techniques. Serial monitoring withCT scans of the chest and serological markers can help withearly identification in high-risk patients, such as hematopoieticstem cell transplant recipients. The most common radiographicfindings are single or multiple nodules, wedge-shapedpleural-based infiltrates, and cavities. The halo sign is the mostsuggestive clue to aspergillosis and is manifested by a macronodulesurrounded by a perimeter of ground-glass opacity.(J Respir Dis. 2008;29(10):405-410)

Invasive pulmonary aspergillosis, part 1: Diagnosis

Acromegaly was diagnosed in a 36-year-old woman who presented with loss of vision in the right eye that had initially involved the peripheral field. MRI scans of the brain revealed a 6 × 6 × 4-cm sellar mass with suprasellar and parasellar extension encasing the right cavernous sinus and carotid artery.

A. Excess growth hormone production from the pituitary gland as a result of a functional adenoma is the most common cause.

B. It remains undiagnosed for up to 10 years on average.

C. The diagnostic test of choice is an oral glucose tolerance test.

D. End-organ manifestations (eg, arthropathy, cranial nerve palsies, diabetes) contribute to overall mortality increase.

Acromegaly was diagnosed in a 36-year-old woman who presented with loss of vision in the right eye that had initially involved the peripheral field. Which statement about acromegaly is NOT true?

Clinical Topics

Acromegaly: A Pop Quiz

A 67-year-old woman noted the appearance of several non-tender, rock-hard, purple-colored nodules on her legs. Her medical history was significant for distant non-Hodgkin lymphoma.

A 67-year-old woman noted the appearance of several non-tender, rock-hard, purple-colored nodules on her legs. Her medical history was significant for distant non-Hodgkin lymphoma. The violaceous color and configuration of the skin lesions suggests which of the following? 

Hard Purple Nodules: Your Dx?

This image of the dorsum of the tongue of a 42-year-old African American woman shows parallel linear black coatings.

After a “swig” of  Kaopectate, this patient noticed tongue discoloration. Is this coincidental, or is there a clinical connection? 

Black Coating on a Woman’s Tongue

The mother of a 10-year-old boy brings him in for evaluation of his moles (which are all benign). During the visit, the mother asks about the lesions on the first 2 knuckles of his right hand; she initially noticed them several months earlier. The boy is otherwise healthy.

White Knuckles

The risk of developing long COVID appears to have decreased substantially over the course of the COVID-19 pandemic, according to a large analysis led by researchers from Washington University School of Medicine in St Louis.

Researchers attributed approximately 70% of the risk reduction to vaccination against COVID-19 and 30% to the evolving characteristics of the virus as new strains emerged and to improved detection and management of the SARS-CoV-2 infection. But while the news is good on its face, study authors say the risk is still real.

 on July 17, compared health records from the US Department of Veterans Affairs for 441 583 veterans with SARS-CoV-2 infection between March 2020 and January 31, 2022, and 4 748 504 uninfected controls. Investigators, led by Ziyad Al-Aly, MD, director of the Clinical Epidemiology Center, and chief of the research and education services at the VA Saint Louis Health Care System, looked specifically at the rates of long COVID 1 year after virus infection during 3 phases of the pandemic: pre-delta (before vaccines were available), the domination of the delta variant, and the period of the omicron variant (beginning December 2021).

Al-Aly and colleagues reported the cumulative incidence of long COVID at 1-year post-infection decreased from a high of 10.42 cases per 100 persons among unvaccinated participants during the pre-delta era to a low of 3.50 cases per 100 persons among vaccinated individuals during the later omicron era.

Looking more closely at vaccinated vs unvaccinated individuals by variant era, 10.42 out of 100 developed long COVID 1 year after infection in the early pandemic months, before vaccines were available. With the arrival and tenure of the delta variant (June 19, 2020, through December 18, 2021) slightly fewer unvaccinated people (9.51 out of 100)received a long COVID diagnosis but just slightly more than half that many who were vaccinated (5.34 out of 100), were diagnosed a year after infection resolved. In the omicron era (began December 19, 2021) long COVID was diagnosed in 7.76 out of 100 unvaccinated people but only in 3.5 out of 100 vaccinated individuals.

The cumulative incidence of long COVID at 1 year was lower per 100 people among vaccinated compared with unvaccinated persons (average difference across delta and omicron eras, -4.22 events).

When they conducted decompensation analyses of the change in cumulative incidence of long COVID over the study period, the team found there were 5.23 fewer long COVID diagnoses per 100 persons 1-year post-infection during the omicron era than during the pre-delta and delta eras combined. Al-Aly and colleagues calculated that 28.11% of the decrease could be attributed variant characteristics during each era while the remainder of the difference, 71.89%, was related to the effect of vaccines.

"These findings suggest that vaccine uptake will be key to maintaining the lower cumulative incidence of PASC [postacute sequelae of severe acute respiratory syndrome] relative to earlier phases of the pandemic," the team wrote. However, Al-Aly also emphasized that even with the overall decline, the lowest rate of long COVID among vaccinated individuals— 3.5% — remains a substantial risk. “That’s three to four vaccinated individuals out of 100 getting long COVID,” he said. “Multiplied by the large numbers of people who continue to get infected and reinfected, it’s a lot of people. This remaining risk is not trivial. It will continue to add an already staggering health problem facing people across the world.”

“We need to double down on our efforts to understand it so we can prevent suffering and treat affected individuals.”

The Centers for Disease Control and Prevention estimates that 6.4% of US adults have experienced long COVID, with prevalence ranging from 1.9% to as high as 10.6% across the country.

 Symptoms can be lingering versions of those experienced during the acute infection or can be altogether new; temporally they can follow resolution of the infection immediately or emerge weeks, even months, after what appears to be recovery from the acute illness. The symptoms range from irritating to debilitating and manifest in persons whose infection was mild or even asymptomatic in addition to those who were hospitalized and critically ill.

Research to date has documented more than 200 symptoms associated with long COVID, the most familiar of those including fatigue, post exertional malaise, heart palpitations, blood clots, hair loss, persistent cough, loss of lung function, muscle pain and joint aches, brain fog, headache, depression, anxiety, sleep disturbances, loss of smell, and gastrointestinal problems.

Individuals who have had COVID-19 may also be more likely to develop new health conditions including diabetes, cardiovascular disease, blood clots, and neurologic disorders.

Among the study’s limitations Al-Aly et al note that the homogeneity of the VA population, ie, older White men, may preclude generalization of the findings to other groups; also, the observational nature invites residual confounding and misclassification bias.

References 
1. Xie Y, Choi T, Al-Aly Z. Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras. 

Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant. 

Long COVID Risk Declined Over the Pandemic and Vaccination was Key, But Risk Remains

Genovefa A. Papanicolaou, MD

Articles

Latest Updated Articles